Humacyte (NASDAQ:HUMA) Receives Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a report issued on Tuesday,Benzinga reports. The brokerage currently has a $25.00 target price on the stock.

HUMA has been the topic of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Humacyte in a report on Monday, December 29th. BTIG Research reissued a “buy” rating and issued a $6.00 price target on shares of Humacyte in a report on Monday, February 9th. UBS Group restated a “buy” rating on shares of Humacyte in a research report on Monday, December 1st. Wall Street Zen downgraded Humacyte from a “hold” rating to a “sell” rating in a research note on Sunday, December 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of Humacyte in a research report on Monday, December 1st. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $8.14.

Humacyte Stock Performance

Shares of HUMA opened at $1.16 on Tuesday. The firm has a market cap of $217.23 million, a price-to-earnings ratio of -5.04 and a beta of 1.89. The company has a quick ratio of 0.90, a current ratio of 1.62 and a debt-to-equity ratio of 2.97. The business’s 50 day moving average is $1.09 and its two-hundred day moving average is $1.32. Humacyte has a 52-week low of $0.88 and a 52-week high of $3.36.

Institutional Investors Weigh In On Humacyte

Several hedge funds and other institutional investors have recently bought and sold shares of HUMA. Caitong International Asset Management Co. Ltd lifted its holdings in Humacyte by 841.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 70,414 shares of the company’s stock valued at $68,000 after acquiring an additional 62,931 shares during the last quarter. Aristides Capital LLC acquired a new position in shares of Humacyte in the 4th quarter worth approximately $156,000. Virtu Financial LLC acquired a new position in shares of Humacyte in the 4th quarter worth approximately $252,000. XTX Topco Ltd lifted its stake in Humacyte by 236.1% during the fourth quarter. XTX Topco Ltd now owns 650,858 shares of the company’s stock valued at $625,000 after purchasing an additional 457,236 shares during the last quarter. Finally, Quadrature Capital Ltd bought a new stake in Humacyte during the fourth quarter worth approximately $201,000. 44.71% of the stock is currently owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.